Combined stem cell and kidney transplant with venetoclax
Treatments studied
Part of Blood & lymphatic, Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests adding the drug venetoclax to a combined stem cell and kidney transplant. It is for people with certain blood cancers who also have kidney failure and need a kidney transplant from a matched relative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a blood cancer that can be cured with a stem cell transplant and is in partial or complete remission.
- You have an HLA-matched or half-matched (haploidentical) relative who can donate both bone marrow (or stem cells) and a kidney.
- You are currently on dialysis or have very low kidney function (creatinine clearance ≤ 35 ml/min).
- Your heart, lung, and liver function are within safe limits for transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial tests whether adding venetoclax (a pill) to a lower-intensity bone marrow or stem cell transplant, and continuing it after transplant, helps prevent acute myeloid leukemia (AML) from coming back. You may join if you are in first remission and have a suitable donor.
Hear when a new Kidney Failure, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.